Stocks Health care OCGN
NASDAQ · Health careOcugen, Inc. (OCGN)
Ocugen, Inc. brought in $4.8M of revenue over the twelve months to September 30, 2026, down 11.0% from a year earlier. It posted a net loss of $65.4M. In fiscal 2025 capital spending exceeded operating cash flow by $57.1M. At September 30, 2026 it held $24.6M in cash against $1.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Ocugen, Inc.
- Net worth
- Ocugen, Inc. has a market value (market cap) of $329.6M at the latest share price, and shareholders' equity of -$17.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.4M (+8.8% year on year), with a net loss of $67.8M. Over the 12 months to September 30, 2026: revenue $4.8M, net loss $65.4M.
- Cash flow
- In fiscal 2025 operations used $57M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ocugen, Inc.'s next report is expected around February 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ocugen, Inc. does
Ocugen, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker OCGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.4M | -$67.8M | n/a | -$57.1M |
| 2024 | $4.1M | -$54.1M | n/a | -$45.5M |
| 2023 | $6M | -$63.1M | -$0.26 | -$72.5M |
| 2022 | $2.5M | -$86.8M | -$0.40 | -$64.5M |
| 2021 | $0 | -$58.4M | -$0.32 | -$48.9M |
| 2020 | $43K | -$21.8M | -$0.33 | -$15M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where OCGN ranks in Health care
Latest SEC filings
What Ocugen, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Additional proxy material DEFA14A
- November 6, 2026Additional proxy material DEFA14A
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $2M versus the same quarter last year; diluted EPS -$0.01 versus -$0.07.
- November 4, 2026
- October 15, 2026
- October 15, 2026
- October 6, 2026
- September 23, 2026
- September 8, 2026
- August 14, 2026Additional proxy material DEFA14A
Insider trades
What the people running Ocugen, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.1M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 9, 2026 | Musunuri ShankarChief Executive Officer, Director | Soldpre-planned (10b5-1) | 468,727 | $445.3K |
| October 9, 2026 | Musunuri ShankarChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 57,264 | $54.4K |
| September 9, 2026 | Musunuri ShankarChief Executive Officer, Director | Soldpre-planned (10b5-1) | 468,727 | $525K |
| September 9, 2026 | Musunuri ShankarChief Executive Officer, Director | Soldpre-planned (10b5-1), indirect | 57,264 | $64.1K |
| June 15, 2026 | Johnson-Greene Treerita EssalimaChief Financial Officer | Bought | 21,000 | $25.8K |
| April 1, 2026 | Zhang JungeDirector | Exercised options | 15,000 | $7.7K |
| April 1, 2026 | Zhang JungeDirector | Exercised options | 112,205 | $51.6K |
| April 1, 2026 | Zhang JungeDirector | Exercised options | 66,929 | $95K |
Who owns OCGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Millennium Management LLC13G, passive with 2 related filers | 5.2% | April 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 147 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 27,002,933 | +19,697,954 |
| State Street Corp | 21,469,307 | +11,799,116 |
| Vanguard Capital Management LLC | 14,372,598 | +568,487 |
| Millennium Management LLC | 13,943,252 | +216,060 |
| Geode Capital Management, LLC | 8,871,013 | +4,643,909 |
| Rtw Investments, LP | 6,666,666 | 0 |
| UBS Group AG | 5,177,508 | -2,102,812 |
| Ikarian Capital, LLC | 3,962,972 | 0 |
| GMT Capital Corp | 3,505,398 | 0 |
| Marshall Wace, Llp | 3,410,257 | -4,642,093 |
| Vanguard Portfolio Management LLC | 3,329,446 | +2,393,647 |
| Hennion & Walsh Asset Management, Inc. | 2,830,397 | +1,553,672 |
| Northern Trust Corp | 2,747,562 | +2,033,826 |
| Vanguard Fiduciary Trust Co | 2,367,144 | +366,041 |
| Two Sigma Investments, LP | 2,230,179 | -21,103 |
| Qube Research & Technologies Ltd | 2,203,407 | -1,569,659 |
| Bank of America Corp | 1,990,636 | +816,456 |
| Boothbay Fund Management, LLC | 1,097,742 | 0 |
| Charles Schwab Investment Management Inc | 1,042,537 | +830,443 |
| Goldman Sachs Group Inc | 1,020,894 | -106,512 |
Insiders
4 insiders reported holding 7,138,657 shares in total, about $6.9M at the last price.
| Holder | Shares |
|---|---|
| Musunuri ShankarChief Executive Officer, Director | 5,049,2411,030,771 held indirectly |
| Zhang JungeDirector | 1,359,316 |
| Johnson-Greene Treerita EssalimaChief Financial Officer | 521,000 |
| Ramachandran RameshChief Accounting Officer | 209,100 |
Questions about OCGN
What does Ocugen, Inc. do?
Ocugen, Inc. is a company in the Health care sector, listed on NASDAQ as OCGN. Its shares trade on NASDAQ under the ticker OCGN.
What is Ocugen, Inc.'s net worth?
Ocugen, Inc. has a market value (market cap) of $329.6M at the latest share price, and shareholders' equity of -$17.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ocugen, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $65.4M on revenue of $4.8M.
How much revenue does Ocugen, Inc. make?
Over the twelve months to September 30, 2026 Ocugen, Inc. reported revenue of $4.8M. That is 11.0% less than a year earlier.
When did Ocugen, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the additional proxy material from November 6, 2026.
When is Ocugen, Inc.'s next earnings report?
Ocugen, Inc.'s next report is expected around February 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare OCGN with
Follow OCGN
Get an email when Ocugen, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ocugen, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.